HK inno.N's GERD drug K-CAB gets approval in Mexico

The gastroesophageal reflux disease treatment has been approved in 4 countries across the world and first in Latin America

HK Inno.N's K-CAB
HK Inno.N's K-CAB
Ji-Hyun Lee 1
2023-02-14 14:42:25 bluesky@hankyung.com
Bio & Pharma

South Korea's biohealth company HK inno.N said on Tuesday that its gastroesophageal reflux disease (GERD) treatment K-CAB (active ingredient: tegoprazan) has been approved by the Mexican Ministry of Health. This marks the first approval of the treatment in a Latin American country.

In Mexico, K-CAB has been approved for use in combination therapy with antibiotics for erosive and non-erosive gastroesophageal reflux disease, gastric ulcer and Helicobacter pylori eradication, under the brand name KI-CAB.

With this authorization, K-CAB was approved in four countries including Mexico, Singapore, Mongolia, and Indonesia. There are 26 countries in the process of reviewing or preparing for approval.

"With the approval in Mexico, K-CAB is set to promote Korean new drugs in Latin America." said Kwak Dalwon, CEO of HK inno.N. "We will further expand the range of the market to Europe and the Middle East so that it can become a global blockbuster drug."

Write to Ji-Hyun Lee at bluesky@hankyung.com
#HK inno.N #gastroesophageal reflux disease #GERD #K-CAB #tegoprazan #korea hk inno.n #hk inno.n gerd k-cab #hk inno.n latin america

HK inno.N to introduce biosimilars for bone disease treatment from Spain

HK inno.N to introduce biosimilars for bone disease treatment from Spain

South Korea's biohealth company HK inno.N said on Wednesday that it has signed an agreement with Spanish pharmaceutical company mAbxience SA to introduce biosimilars of bone loss treatment Prolia and Xgeva.Under the terms of the agreement, HK inno.N plans to apply for permits by acquiring dome

HK inno.N's K-CAB to get insurance benefits in China

HK inno.N's K-CAB to get insurance benefits in China

HK inno.N's K-CAB South Korea’s 30th novel medicine K-CAB Tab (active ingredient: tegoprazan), a gastroesophageal reflux disease (GERD) treatment of HK inno.N, will receive insurance coverage in China.According to industry sources on Thursday, K-CAB Tab was included in the National Reimbu

HK inno.N gets approval to sell K-CAB in Singapore

HK inno.N gets approval to sell K-CAB in Singapore

HK inno.N's K-CAB South Korean biohealth company HK inno.N said on Wednesday that it has received an item approval for K-CAB, a new drug for gastroesophageal reflux disease (GERD), from Singaporian authorities.K-CAB is the 30th domestic new drug released by HK inno.N in 2019 and is a new potass

HK inno.N receives sales permit for ulcer treatment in China

HK inno.N receives sales permit for ulcer treatment in China

HK inno.N scientist at a lab in Hanam, Gyeonggi Province HK inno.N is expediting its global expansion with its latest drug K-Cab designed to treat peptic ulcers.The South Korean pharmaceutical company announced Thursday it received the sales permit from China’s National Medical Products
(* comment hide *}